Squarex unveils Phase 2 results of SQX770 in recurrent herpes labialis
Category: #health  | By Mateen Dalal  | Date: 2019-08-06 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Squarex unveils Phase 2 results of SQX770 in recurrent herpes labialis

The study involved around 139 subjects who had reported four or more episodes of herpes labialis in the past 12 months

Squarex, a clinical-stage pharmaceutical company has reportedly unveiled the positive results from a Phase 2 clinical trial of its investigational compound, SQX770, which is a tropical formulation of the immunomodulator squaric acid dibutyl ester, in patients with oral herpes.

Apparently, the company aims to initiate a Phase 3 study after a planned FDA end of Phase 2 clinical meeting later in the year.

Sources close to the matter informed that the placebo-controlled, multi-center, double-blinded randomized Phase 2 study involved around 139 subjects who had reported four or more episodes of herpes labialis in the past 12 months. The study was formally designed to ascertain if the topical application of SADBE is able to delay HSV-1 outbreaks.

Seemingly, results from the Phase 2 clinical trial defined that a single topical dosage of SQX770 applied to the upper arm substantially extended time to subsequent herpes labialis outbreak and reduced both the severity and frequency of outbreaks. The greatest effect was registered during days 43 to 121 following the application of drug. These findings indicate SQX770 immunotherapy can take up to 6 weeks to completely exert a clinically significant effect on the immune system.

Sources further stated that no serious adverse events were reported so far. The adverse events that were officially reported, like local reaction owing to the sensitization and challenge responses on the skin, were what investigators anticipated to witness using a topical immunomodulator.

According to Jack Talley, Chief Executive Officer of Squarex, the company’s findings confirm and validate the results from two former studies including a prior placebo controlled clinical trial and therefore, open the way for the initiation of a Phase 3 clinical trial. With no existing preventative treatment options available on the market for the millions of patients who are suffering from recurrent HSV-1 outbreaks, Squarex is ready to continue the clinical development and could expectedly bring the first and only option for combating herpes labialis.

Source Credits: https://www.prnewswire.com/news-releases/squarex-announces-positive-results-from-completed-phase-2-study-of-sqx770-in-the-prevention-of-recurrent-herpes-labialis-300896065.html

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

UK’s Health Secretary announces 10-year plan to tackle dementia

UK’s Health Secretary announces 10-year plan to tackle dementia

By Mateen Dalal

The UK Health and Social Care Secretary, Sajid Javid, has reportedly announced a novel 10-year plan to effectively tackle dementia and to increase funding in research to get a better understanding of neurodegenerative diseases. As per sources, at ...

Starbucks to cover abortion related travel expenses for workers

Starbucks to cover abortion related travel expenses for workers

By Mateen Dalal

Starbucks has reportedly announced that it would start covering all eligible travel expenditures for the workers seeking gender-affirming surgical procedures or abortions. As per reports, the coffee conglomerate has joined Apple, Amazon, Salesforc...

Russia-Ukraine war puts UK fish & chips industry in severe jeopardy

Russia-Ukraine war puts UK fish & chips industry in severe jeopardy

By Mateen Dalal

The on-going conflict between Russia and Ukraine has adversely affected the fish and chips industry in the United Kingdom, driving the closure of centuries-old shops, sharp price hikes, and change in menus. The National Federation of Fish Friers (...